Individualized Texting for Adherence Building (iTAB) Improves cART adherence in HIV-infected Persons with Co-occurring Bipolar Disorder

D.J. Moore, A. Poquette, C. Posada, K. Blackstone, B. Gouaux, J. Badiee, I. Grant, J.H. Atkinson & the HNRP Group



University of California, San Diego Department of Psychiatry



HIV, Bipolar Disorder & Adherence

- Among HIV+, ART adherence has improved with less complex regimens, but is still a problem
- 40 60% of BD are non-adherent to psychotropics; nonadherent BD pts. are at higher risk of:
 - » Relapse/Recurrence of mood episode
 - » Hospitalization
- Risks for increased non-adherence in HIV+/BD+ include:
 - » Incresed # of medications, mood instability, substance abuse/dependence, cognitive difficulties, etc.



Public health importance of HIV+/BD+: Poor adherence \rightarrow Worse health outcomes

Parienti et al., CID, 2009; Scott and Pope, Am. J. Psych., 2002; Li et al., 2002; Scott and Pope, JCP, 2002





Texting Improves ART Adherence

- SMS (texting) interventions for improving ART adherence show promise
- In a 2012 Cochrane report, two RCTs shown to be efficacious for ART improvement:
 - » 1X week text over a 12-month interval decreased non-adherence and virologic failure (Lester et al., 2010)
 - » 1X week versus 1X day text messages; at 48-weeks, weekly messages were more likely to reduce non-adherence and treatment interruptions (Pop-Eleches et al., 2011)
- Optimal texting systems for adherence improvement in difficult-to-treat populations in US still evolving

Horvath et al., Cochran Report, 2012; Lester et al., 2010; Pop-Eleches et al. 2011





Aim & Hypothesis

AIM:

To compare individualized texting for adherence building (iTAB) vs. active control (CTRL) on antiretroviral (ARV) and psychotropic (PSY) medication adherence among HIV-infected persons with co-occurring bipolar disorder (HIV+/BD+)

HYPOTHESIS:

 Participants assigned to iTAB will show superior ARV and PSY adherence and better therapeutic coverage as compared to CTRL



HIV NEUROBEHAVIORAL RESEARCH PROGRAM | UNIVERSITY OF CALIFORNIA, SAN DIEGO 👘 🔫 🕖



Personalized iTAB intervention

- Both iTAB and CTRL received:
 - Adherence psychoeducation (~30 min)
 - A daily text message asking about mood
 - Process of medication reminder creation
 - Identify sentinel med for MEMS: <u>ARV</u>: Mostly fixed-dose combination medication; <u>PSY</u>: Primary mood stabilizer

ITAB – Pts create personalized med reminder texts:

- <u>Description of medications</u>
- <u>Personalized reminder stems</u> (e.g., "remember to take your meds, they make you healthy")
- Preferred name
- Ideal time for reminders each day by med



iTAB Intervention Stems

Stems of personal reminder messages reflect different themes:


- » Celebrate Health
 - Stay healthy! It's time 2 take ur meds, pls take ur...
- » Time and Focus
 - It's pill time! Take ur...
- » Control Disease
 - Taking ur meds helps control ur disease. Rmber 2 take ur...

- » Empowering
 - It's med time, only u can control this. Rmber 2 take ur...
- » Importance of Adherence
 - Adherence is impt. Pls take ur...





iTAB Decision Tree



Other iTAB components:

- 3 consecutive days of nonresponses get a
 - "noncompliance" text
- 5 consecutive days of nonresponses, call from RA
- Adherence Targets: "Ur current adherence: xx%.
 Adhr when u take ur next dose: xx% (x/x doses)"
- Personalized Reinforcer




iTAB Inclusion Criteria

- 18 years or older at time of enrollment
- HIV-infected and on ART
- Current bipolar diagnosis as determined via diagnostic interview (i.e., CIDI) and taking a psychotropic medication to treat BD
- Willingness to receive daily text messages
- Willingness to track medication via MEMS for 30 days



UCSD

Sample to Date





HIV NEUROBEHAVIORAL RESEARCH PROGRAM | UNIVERSITY OF CALIFORNIA, SAN DIEGO 🛛 🔫 UCSD

Demographics

	CTRL (n=22)	ITAB (n=20)	P-value
Age	46.3 (10.7)	49.3 (9.2)	0.38
Education	13.3 (3.1)	13.6 (2.1)	0.70
Ethnicity (% White)	45.5	70.0	0.11
Sex (% Male)	81.8	95.0	0.17
Global Deficit Score	0.74 (0.76)	0.51 (0.41)	0.49
Estimated Verbal IQ	100.3 (17.9)	98.3 (17.0)	0.62



.



.................

Psychiatric Characteristics

	CTRL (n=22)	ITAB (n=20)	P-value
Lifetime Substance Dependence,%	77.3	55.0	0.13
Current Substance Dependence, %	4.6	5.3	0.92
Euthymic during study period, %	68.2	70.0	0.90
Beck Depression Inventory–II	17.9 (10.8)	14.7 (10.3)	0.26
Young Mania Rating Scale	5.6 (4.6)	5.8 (6.3)	0.54
GAF	66.6 (10.9)	69.7 (8.9)	0.27





Medical Characteristics

	CTRL (n=22)	ITAB (n=20)	P-value
Current CD4 Count	655.8 (324.2)	603.4 (392.8)	0.56
Nadir CD4 Count	225.7 (153.1)	281.2 (258.2)	0.73
HIV RNA Detectable, %	9.5	25.0	0.18
AIDS Status, %	63.2	60.0	0.85
HCV Status, %	31.8	25.0	0.63






Medication Characteristics

	CTRL (n=22)	ITAB (n=20)	P-value
Duration ARV regimen, months	49.2 (43.1)	30.5 (22.3)	0.40
Total No. of pills per day, all meds	14.7 (8.8)	18.3 (10.8)	0.13
Once daily ARV, %	90.9	85.0	0.55
Once daily PSY, %	86.4	85.0	0.90




Overall MEMS Adherence by Group





축 UCSD


Time from Target Dose by Group





< UCSD

ARV and PSY Dose Timing



Z = -4.78, *p*< 0.001


Z = -8.45, *p*< 0.001

Time of ARV and PSY dose was significantly more clustered around target time for iTAB group






All: Mood Responsiveness & Adherence





축 UCSD


iTAB: Mood Responsiveness & Adherence





र UCSD

CTRL: Mood Responsiveness & Adherence





🗢 UCSD

Conclusions & Future Directions

• iTAB as compared to CTRL in difficult-to-treat HIV+/BD+:

- 1. Trend toward improved ARV adherence; medium effect size
- Significantly better dose timing → improves therapeutic coverage
- Daily mood text message not associated with improved adherence in the CTRL group, arguing for the value of personalized reminders
- Future studies with iTAB will:
 - 1. Evaluate the utility in HIV+ active METH users
 - 2. Assess the intervention over longer periods of time & assess frequency of reminders
 - 3. Determine the utility of iTAB for PrEP





Acknowledgments

Participants

Funding Support

- » California HIV/AIDS Research Program IDEA Award #ID-09-047
- » NIDA R34 DA31058
- » NIMH/CSPAR P30 MH062512

Co-investigators/Consultants

- » J. Hampton Atkinson, M.D.
- » Colin A Depp, Ph.D.
- » Igor Grant, M.D.
- » Scott Letendre, M.D.
- » Tom Patterson, Ph.D.
- » Steven Safren, Ph.D.

Dr. Moore's Trainees

- » Kaitlin Blackstone
- » Carolina Posada
- » Jessica Montoya

Staff

- » Amelia J. Poquette *
- » Ben Gouaux *
- » Jayraan Badiee
- » Nichole Duarte
- » Terry Alexander, R.N.
- » Roberto Gallardo
- » Crossby Vargas
- » Rodney von Jaeger
- » Jenn Marquie-Beck
- » Candy Carson
- » Mel Willard
- Cal-IT2 Technical Experts
 - » Kevin Patrick, M.D., M.S.
 - » Fred Raab
 - » Mark Sullivan *









HIV NEUROBEHAVIORAL RESEARCH PROGRAM | UNIVERSITY OF CALIFORNIA, SAN DIEGO

